(Non-exhaustive) List of drugs being tested for repurposing for COVID-19

# Jakavi (Ruxolitinib) - originally developed for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow.

# Remdesivir - originally developed for the Ebola and Marburg viruses.

# Chloroquine and Hydroxychloroquine - originally developed for treating malaria.

# Baricitinib - originally developed for treating rheumatoid arthritis.

# Kaletra (Lopinavir/Ritonavir) - originally developed for treating and preventing HIV/AIDS.

# Actemra (tocilizumab)- originally developed for treating rheumatoid arthritis.

# Avigan (favipiravir) - originally developed for treating influenza viruses.

# Kevzara (sarilumab) - originally developed for treating rheumatoid arthritis.

# Nafamostat - originally developed as a short-acting anticoagulant.

# Ivermectin - originally developed to treat many types of parasite infestations.

# EIDD-2801 - N4-hydroxycytidine and its prodrug EIDD-2801 is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.

# LAU-7b - LAU-7b is an analogue of the retinoid fenretinide (related to vitamin A) that may help reduce the inflammatory response in the lungs of people with cystic fibrosis.

# LY3127804 - LY3127804 is an investigational drug currently in clinical trials for treating patients with advanced or metastatic solid tumors.

# Famotidine - is a medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome.